Lung Cancer
Volume 69, Issue 1 , Pages 46-50 , July 2010

Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer

  • Anne Mathieu

      Affiliations

    • Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, B-1070 Brussels, Belgium
    • ,
  • Birgit Weynand

      Affiliations

    • Cliniques Universitaires St Luc, Université Catholique de Louvain (UCL), Brussels, Belgium
    • ,
  • Eric Verbeken

      Affiliations

    • Universitair Ziekenhuis Gasthuisberg, Katholieke Universiteit Leuven (KUL), Leuven, Belgium
    • ,
  • Susana Da Silva

      Affiliations

    • N.V. Roche S.A., Brussels, Belgium
    • ,
  • Christine Decaestecker

      Affiliations

    • Laboratory of Toxicology, Institute of Pharmacy, Université Libre de Bruxelles (ULB), Brussels, Belgium
    • Laboratory of Image Analysis and Synthesis, Université Libre de Bruxelles (ULB), Brussels, Belgium
    • ,
  • Isabelle Salmon

      Affiliations

    • Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, B-1070 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 025553115; fax: +32 025554790.
    • ,
  • Pieter Demetter

      Affiliations

    • Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, B-1070 Brussels, Belgium

Received 13 March 2009 ,Revised 17 August 2009 ,Accepted 3 September 2009.

References 

  1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  3. Reck M, Crino L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer. 2009;63:1–9
  4. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160–1174
  5. Metro G, Finocchiaro G, Capuzzo F. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Ann Oncol. 2006;17(Suppl. 2):ii42–ii45
  6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Eng J Med. 2005;353:123–132
  7. Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors—the bull's-eye hits the arrow. Cancer Cell. 2004;5:411–415
  8. Parra HS, Cavina R, Latteri F, Zucali PA, Campagnoli E, Morenghi E, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’ ZD1839) in non-small-cell lung cancer. Br J Cancer. 2004;91:208–212
  9. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238–3247
  10. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144
  11. Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol. 2005;16:538–548
  12. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–3807
  13. Italiano A, Burel Vandenbos F, Otto J, Mouroux J, Fontaine D, Marcy PY, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol. 2006;17:981–985
  14. Mukohara T, Kudoh S, Matsuura K, Yamauchi S, Kimura T, Yoshimura N, et al. Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC. Anticancer Res. 2004;24:11–17
  15. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997;3:515–522
  16. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Instit. 2005;97:643–655
  17. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10:4227s–4232s
  18. Buckley AF, Kakar S. Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol. 2007;15:305–309
  19. Penault-Llorca F, Cayre A, Arnould L, Bibeau F, Bralet MP, Rochaix P, et al. Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?. Oncol Rep. 2006;16:1173–1179
  20. Meert AP, Martin B, Verdebout JM, Paesmans M, Berghmans T, Ninane V, et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer. 2004;44:295–301
  21. Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005;103:1265–1273
  22. Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: The EGFR fluorescence in situ hybridization assay. Diagn Pathol. 2006;1:19
  23. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007;18:752–760
  24. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Eng J Med. 2004;350:2129–2139
  25. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500
  26. Sakurada A, Shepherd FA, Tsao MS. Epidermal growth factor tyrosine kinase inhibitors in lung cancer: Impact of primary or secondary mutations. Clin Lung Cancer. 2006;7:S138–S144
  27. Joshi AS, Sharangpani GM, Porter K, Keyhani S, Morrison C, Basu AS, et al. Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A. 2007;71:273–285
  28. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer. 2006;8:30–38
  29. Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol. 2008;20:162–175
  30. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–1818
  31. Pesek M, Benesova L, Belsanova B, Mukensnabl P, Bruha F, Minarik M. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res. 2009;29:2767–2773
  32. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with our without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932–20937

PII: S0169-5002(09)00487-5

doi: 10.1016/j.lungcan.2009.09.003

Lung Cancer
Volume 69, Issue 1 , Pages 46-50 , July 2010

Article Tools

* Image Usage & Resolution